1. Home
  2. SKYH vs FULC Comparison

SKYH vs FULC Comparison

Compare SKYH & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sky Harbour Group Corporation

SKYH

Sky Harbour Group Corporation

HOLD

Current Price

$10.38

Market Cap

327.2M

Sector

Industrials

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$3.82

Market Cap

285.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKYH
FULC
Founded
2017
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
327.2M
285.4M
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
SKYH
FULC
Price
$10.38
$3.82
Analyst Decision
Strong Buy
Buy
Analyst Count
4
8
Target Price
$13.13
$16.38
AVG Volume (30 Days)
183.4K
1.7M
Earning Date
05-12-2026
04-27-2026
Dividend Yield
N/A
N/A
EPS Growth
105.11
N/A
EPS
N/A
N/A
Revenue
$27,540,000.00
N/A
Revenue This Year
$78.89
N/A
Revenue Next Year
$73.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
86.57
N/A
52 Week Low
$8.22
$2.83
52 Week High
$11.70
$15.74

Technical Indicators

Market Signals
Indicator
SKYH
FULC
Relative Strength Index (RSI) 47.10 51.36
Support Level $10.25 $3.44
Resistance Level $10.41 $3.96
Average True Range (ATR) 0.41 0.12
MACD -0.12 0.03
Stochastic Oscillator 20.76 64.62

Price Performance

Historical Comparison
SKYH
FULC

About SKYH Sky Harbour Group Corporation

Sky Harbour Group Corp is an aviation infrastructure company focused on building the first nationwide network of Home Base Operator (HBO) campuses designed exclusively for business aircraft. The company develops, leases, and manages general aviation hangars across the United States, targeting airfields in markets with aircraft populations and high hangar demand. Its HBS campuses include private hangars and offer a range of services tailored to aircraft owners operating from these facilities. The majority of the company's revenue is derived from the leasing of home-based aircraft hangars and through services and products ancillary to its leasing activities.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: